SCHEMBL348977

SCHEMBL348977

CCOC(=O)c1sc(-n2c(=O)[nH]c3ccccc32)nc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KIF15 Q9NS87 1/20 0.52
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GAA P10253 1/20 0.49
ADORA3 P0DMS8 3/20 0.48
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.45
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C9 P11712 1/20 0.44
CDC7 O00311 1/20 0.44
DBF4 Q9UBU7 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347288 0.84 AURKA (0.47) KMT2ASMN1; SMN2KDM4EAURKA
SCHEMBL2256170 0.75 SMN1; SMN2 (0.78) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL244736 0.74 ALDH1A1 (0.57) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL348046 0.73 L3MBTL1 (0.57) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL28496776 0.73 MAT2A (0.65) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL13037513 0.72 KDM4E (0.55) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL21467333 0.72 KDM4E (0.52) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL187838 0.72 MAPT (0.51) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL13037514 0.72 ALDH1A1 (0.58) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL242637 0.71 KMT2A (0.51) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318949-B2 Organic compounds NOVARTIS AG (CH) 2012-11-27 US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 US disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014906-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 MEN1 4876/4885KMT2A 2098/4885MAPT 2947/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 MEN1 4876/4885KMT2A 2098/4885MAPT 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.